IMD Drug Screening for Kidney Cancer
Trial Summary
Will I have to stop taking my current medications?
The trial protocol does not specify whether you need to stop taking your current medications. It is best to discuss this with the medical team conducting the trial.
What data supports the effectiveness of the treatment Implantable Microdevice (IMD) for kidney cancer?
Research on implantable microdevices shows they can safely test how well different cancer drugs work directly inside the body, which helps in creating personalized treatment plans. This approach has been tested in lung cancer and other tumor models, suggesting it could be useful for kidney cancer as well.12345
How is the Implantable Microdevice (IMD) treatment for kidney cancer different from other treatments?
The Implantable Microdevice (IMD) is unique because it allows for localized, controlled drug delivery directly at the tumor site, enabling personalized cancer treatment by assessing multiple drug responses in vivo (inside the body). This approach contrasts with traditional systemic treatments that often involve oral or injectable drugs, which can lead to fluctuating drug levels and broader systemic exposure.12367
What is the purpose of this trial?
This research is being done to study the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of 19 specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against metastatic renal cell carcinoma (RCC).The name of the intervention(s) involved in this study are:* Implantable Microdevice (IMD)* Surgery (excision of tumor)* Drugs used in this study will only include drugs already used as standard of care for the treatment of metastatic renal cell carcinoma (RCC)
Research Team
Wenxin Xu, MD
Principal Investigator
Dana-Farber Cancer Institute
Eligibility Criteria
This trial is for adults with metastatic renal cell carcinoma who are stable enough for surgery and have a tumor at least 1cm in size. They must be evaluated by an oncologist, have certain blood count levels, and agree to genetic testing. People with uncontrolled illnesses or bleeding disorders that increase surgical risks can't participate.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Implantation and Initial Evaluation
Placement of 1-6 microdevices into the tumor, followed by surgical removal and analysis after approximately 3 days
Standard of Care Treatment
Participants undergo standard of care surgery and receive standard cancer treatment drugs
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Implantable Microdevice (IMD)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Wenxin Xu
Lead Sponsor